Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocugen Inc
(NQ:
OCGN
)
0.9110
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocugen Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
32
33
Next >
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Pharma Market Research Conference
January 31, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
January 16, 2024
From
Ocugen
Via
GlobeNewswire
Recap: Ocugen Q3 Earnings
November 09, 2023
Via
Benzinga
Earnings Outlook For Ocugen
November 08, 2023
Via
Benzinga
A Preview Of Ocugen's Earnings
August 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 02, 2024
Via
Benzinga
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
December 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
December 19, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 13, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 29, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
November 10, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen (OCGN) Q3 2023 Earnings Call Transcript
November 09, 2023
OCGN earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
November 07, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
November 02, 2023
From
Ocugen
Via
GlobeNewswire
Why Is Archer Aviation (ACHR) Stock Moving Today?
October 10, 2023
Archer Aviation stock is on a wild ride Tuesday morning after a short report targeting one of its rivals sent ACHR shares down this morning.
Via
InvestorPlace
Why Is Ocugen (OCGN) Stock Up 5% Today?
October 10, 2023
Ocugen stock is rising higher on Tuesday thanks to OCGN investors celebrating news of a new clinical trial for its Covid-19 vaccine.
Via
InvestorPlace
Exposures
COVID-19
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
October 10, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
October 04, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
September 29, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12, 2023
Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
From
Ocugen
Via
GlobeNewswire
Ocugen (OCGN) Q2 2023 Earnings Call Transcript
August 22, 2023
OCGN earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
August 18, 2023
From
Ocugen
Via
GlobeNewswire
3 Millionaire-Maker Growth Stocks to Buy Before the Window
July 25, 2023
Although millionaire-maker stocks to buy present wildly outrageous risks, the intrepid may find opportunity in these ideas.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.